Purple Biotech (PPBT) announced that it received a letter from the listings qualifications department of Nasdaq notifying the company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the company’s American depositary shares has been below the minimum $1.00 per share requirement under Nasdaq Listing Rule 5550 for 30 consecutive trading days.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PPBT:
- Purple Biotech Enters New ATM Agreement with H.C. Wainwright
- Purple Biotech Unveils Promising Cancer Treatment Developments in September 2025 Update
- Purple Biotech Secures European Patent for NT219 Combinations
- Purple Biotech receives intention to grant a European patent covering NT219
- Purple Biotech Announces $18 Million Public Offering to Boost Oncology Pipeline